ImmuPharma PLC 2024 AR2
The report details ImmuPharma plc's financial and strategic performance for the year ended December 31, 2024. The company made significant scientific progress on its P140 autoimmune technology platform, clarifying its mechanism of action and advancing clinical trial designs for SLE and CIDP. Financially, ImmuPharma reduced its operating loss to #2.7 million from #3.1 million in 2023, while maintaining tight control over cash resources. Additionally, the company realized #1.5 million in gross proceeds from selling its investment in Incanthera plc to support ongoing operations.
Company: ImmuPharma PLC
Sector: Health Care
Country: United Kingdom
Year: 2024
Type: AR2
Pages: 88
ImmuPharma PLC
Report And Consolidated Financial Statements
The report details ImmuPharma plc's financial and strategic performance for the year ended December 31, 2024. The company made significant scientific progress on its P140 autoimmune technology platform, clarifying its mechanism of action and advancing clinical trial designs for SLE and CIDP. Financially, ImmuPharma reduced its operating loss to #2.7 million from #3.1 million in 2023, while maintaining tight control over cash resources. Additionally, the company realized #1.5 million in gross proceeds from selling its investment in Incanthera plc to support ongoing operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees